Barcelona Bàsquet Lose Nebo and Evbuomwan: A Thinned Frontcourt and a Misplaced Line in the Bulletin

Inside FC Barcelona Bàsquet's medical bulletin, one word sits in the wrong place. The headline says foot injury. The body specifies the right soleus. The soleus is not in the foot. It is a deep, flat, elongated muscle sitting beneath the calf, running from below the knee to the ankle, absorbing most of the load every time a man weighing more than a hundred kilograms pushes off the floor. The foot is where people point when they want to signal a serious injury. The soleus is the muscle nobody names, until it tears. That day at the Ciutat Esportiva Joan Gamper, as the bulletin tells it, Josh Nebo left the session with the name of that muscle left behind on paper. He is a centre, a pívot, the kind of player an entire defensive system leans on. He is expected to miss two to three weeks. In the same bulletin, on another line, Tosan Evbuomwan — a forward barely into his twenties — is awaiting a new evaluation of his left shoulder. He suffered a subluxation while on duty for the Great Britain national team. Two lines. One training session. One international window. And a headline that is wrong. Tonight the arena whispers — and I hear basketball breathing. I sat with this bulletin longer than necessary, the way I sit with a game whose result was settled in the third quarter. What is worth reading here is not the two names. What is worth reading is the way a piece of medical information is packaged, and that packaging tells us more about the state of a club than the information itself. A MEDICAL BULLETIN, AND WHAT IT DOES NOT SAY Let us be precise from the start: the source is a club-level medical bulletin. It contains no statistical figure of any kind. No scoring average, no rebound count, no efficiency rating, no games missed this season. No head coach's name. Not one line about contracts or payroll. For a writer, this is an easy trap. When numbers are absent, people fill the gap with emotion. I have fallen into that trap many times across thirty-two years at the desk. So this time I set a rule: wherever the source is silent, I say the source is silent. I do not turn inference into statistics. I do not turn a guess into a claim. And I do not use that silence as permission to embroider. From my experience covering EuroLeague and Liga ACB games across many seasons, I know exactly what readers ask after a bulletin like this: how many points does Nebo cost you, what does Evbuomwan contribute, who is left in the frontcourt. The bulletin answers none of it. It answers exactly one question, and answers it clearly: two frontcourt players are unavailable, one through a soleus, one through a shoulder. The interesting part is the word "otro". In Spanish, "otro lesionado" means "another injured player". That word does not describe Nebo's soleus. It describes a habit. It says the writer has been counting, and the count does not stop at one. This is the only signal of an accumulating pattern in the entire text, and it sits in the headline rather than in the data. I have written about training injuries more often than I would like. They share one feature: nobody filmed them. There is no contact to rewind, to analyse, to blame on an opponent. There is a player, a floor, and a muscle. When an injury happens in training, the natural question points inward, toward the medical room, not outward toward the court. THE SOLEUS, AND THE NAME NOBODY SAYS Nebo is a centre. In European basketball, the word pívot carries a much narrower meaning than "center" in the American professional league. A EuroLeague pívot lives on three dry tasks: screening in the two-man game and rolling to finish at the rim; crashing the offensive glass; and standing as the last line in the defensive scheme. None of it makes a highlight reel. All of it depends on one thing: the ability to push a body off the floor, over and over, forty times a game. The soleus does that work. It is not the jumping muscle. It is the muscle that keeps you balanced as you jump, and absorbs force as you land. A centre with a compromised soleus does not lose the ability to jump — he loses the ability to jump the second time, the third time, the twentieth time. In a EuroLeague game that amounts to being withdrawn from most offensive rebounding contests and being targeted on every switch. From my experience covering games, this is an injury European medical staffs handle with a fairly standard formula: short full rest, then graded reintegration, then a minutes limit for a week or two. The two-to-three-week window in the bulletin sits inside that formula, which means the probability that this is a non-structural soft-tissue injury is high. Medically, that is good news. Tactically, it is still bad news. Losing a pívot is not losing a starting slot. It is losing a function. Without Nebo, the side pick-and-roll loses its roller, and the defence loses its backstop. A coach must choose between two patches: slide a tall forward up to centre, or go small with five players spaced to the perimeter. The first thins the forward line further. The second removes the last layer of defensive insurance. This is where two injuries in one bulletin start to add up into something different in kind. The team has not lost two players. The team has lost the two players who were each other's cover. THE CALENDAR PROBLEM One detail needs to sit in its proper place: "two to three weeks" is a unit of time, not a unit of games. In European basketball the two are never equal. A EuroLeague double-week contains two games, usually two or three days apart, in two different countries. Add a Liga ACB fixture at the weekend and a player can appear in three games in seven days. Multiplied by two or three weeks, that absence equals four to six official games depending on the specific schedule — and that is an estimate drawn from league structure, not from the bulletin. Four to six EuroLeague games is enough volume to move a team's position during a stretch where every result counts toward tiebreakers. But I want to raise a less discussed consequence: during that window, the remaining frontcourt players must play more. Not slightly more. More in a cumulative way, game after game, before the body has recovered from the last one. This is what people call concentration risk. It has a cruel property: it does not appear in this week's medical bulletin. It appears in the bulletin three weeks from now. A TWENTY-YEAR-OLD'S SHOULDER Meanwhile, on another line of the bulletin, there is Evbuomwan. Subluxation is the medical term for a joint partially slipping out of position and then returning on its own. It is often confused with full dislocation, and that confusion has consequences. A full dislocation is an event: it happens, people see it, they put it back. A subluxation is a condition: it has happened, and afterwards the joint develops a tendency to happen again. For a forward barely past twenty, this is the injury I dislike writing about most, because it has no straight recovery line. The shoulder is the body's most mobile joint and its least structurally stable. A forward lives on three things: rebounding in traffic, finishing through contact, and defending with his body. All three run through the shoulder. An ankle can be taped. A knee can be braced. A shoulder is harder — taping strong enough to stabilise is often tight enough to restrict reach, and a forward with restricted reach is a forward limited in his single most important skill. But the most important detail in Evbuomwan's line is three words long: "new evaluation". In the language of sports medical rooms, a new evaluation is not administrative procedure. It signals that the first diagnosis was inconclusive, or that the earlier conclusion is now doubted, or that the timeline is being reset. When a club feels confident enough to publish a two-to-three-week window for one player but says only "under evaluation" for another, that asymmetry is deliberate. That asymmetry tells me the shoulder situation is less predictable than hoped. DECEPTION, AND WHAT IS BEING DECÉIVED